Showing results (201-210 of 270) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Ebiomedicine|November 14, 2022
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialValentina Guarneri, Fara Bras-Maristany, Maria Vittoria Dieci, et al.
JAMA Oncology|February 13, 2025
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical TrialMaria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, et al.
Journal of Translational Medicine|March 5, 2024
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patientsGiulia Pasello, Aline S C Fabricio, Paola Del Bianco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Moira Ragazzi, Bethania Fernandes, et al.
NPJ Breast Cancer|February 20, 2025
Temporal evolution of breast cancer brain metastases treatments and outcomesMichele Bottosso, Gaia Griguolo, Severine Guiu, et al.
Breast (Edinburgh, Scotland)|February 7, 2020
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological modelLuisa Carbognin, Michele Simbolo, Anna Caliò, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohortLuca Visani, Ivica Ratosa, Rupert Bartsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2025
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trialFederica Miglietta, Manon De Graaf, Claudio Vernieri, et al.
Pageof 27